Skip to main content

Table 2 Associations between PDCD4 down-regulation and the clinicopathologic parameters of patients with solid tumors

From: The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis

Parameter Study subjects Reference(s) Total cases PDCD4 expression (cases)a OR 95% CI I 2 (%) P
Negative Positive
Tumor size (large vs. small) Tumor type
 Digestive system cancer [7, 1416] 530 114 vs. 169 84 vs. 163 1.49 1.00–2.22 51.3 0.08
 Urinary system cancer [17] 66 6 vs. 29 5 vs. 26 1.08 0.29–3.95 NA NA
Total   596 120 vs. 198 89 vs. 189 1.45 0.99-2.12 40.8 0.13
T category (T3 + 4 vs. T1 + 2) Tumor type
 Digestive system cancer [15, 19] 238 96 vs. 24 95 vs. 23 0.98 0.46-2.08 25.1 0.26
 Urinary system cancer [17] 66 22 vs. 13 8 vs. 23 4.87 1.69–14.0 NA NA
 Head and neck cancer [18] 190 44 vs. 73 16 vs. 57 2.15 1.10–4.19 NA NA
Total   494 162 vs. 110 119 vs. 103 1.68 0.82–3.43 60.8 0.04
N category (N+ vs. N) Tumor type
 Digestive system cancer [15, 19, 23] 465 164 vs. 119 91 vs. 91 1.02 0.53-1.93 58.5 0.05
 Head and neck cancer [20, 21] 114 19 vs. 36 11 vs. 48 3.39 0.59-19.53 55.3 0.14
 Respiratory system cancer [22] 124 44 vs. 59 11 vs. 10 0.68 0.26–1.74 NA NA
Population
 Asian [15, 1921, 23] 579 183 vs. 155 102 vs. 139 1.26 0.68–2.33 58.8 0.02
 European [22] 124 44 vs. 59 11 vs. 10 0.68 0.26–1.74 NA NA
Total   703 227 vs. 214 113 vs. 149 1.15 0.67–1.68 55.4 0.03
M category (M+ vs. M) Tumor type
 Urinary system tumor [17] 66 22 vs. 13 8 vs. 23 4.87 1.69–14.0 NA NA
 Head and neck cancer [18] 190 10 vs. 107 4 vs. 69 1.61 0.49–5.34 NA NA
 Digestive system cancer [19, 23] 213 4 vs. 117 4 vs. 88 0.72 0.09–5.83 54 0.14
Total   469 36 vs. 237 16 vs. 180 2.51 1.20–5.26 46.2 0.10
  1. OR odds ratio, CI confidence interval, NA not available
  2. aThe data of PDCD4 expression are expressed as the number of cases in the former subgroup versus the number of cases in the latter subgroup, e.g., the number of cases in the large tumor subgroup versus the number of cases in the small tumor subgroup